'This company needs cash to fund the burden of proof and get the product to market.'

Well, in a nutshell that's it isn't it?  That's the whole issue right there.  I may be wrong, but I think that the whole weak biotech market argument is pretty much an excuse for things not moving forward.  If you have a promising drug that has some pretty solid research behind it, not to mention the encouraging results of albeit underpowered but still a fairly substantial trial, then the money will find you…..for sure  The players with money are out there and they are almost certainly aware of RVX and apabetalone.   Eversana, if they were doing anything at all, would undoubtedly have seen to that.  But, nobody seems  interested.  Why?  It's not like (in the big scheme of things) that much money is needed to get this thing moving.

Somebody mentioned the Chinese ownership and that may be a factor.  I doubt if it’s management because if the money is there then even Don can be negotiated away.  Maybe tada is right, maybe the drug ultimately has too much potential and would interfere with existing patented products, but if that’s the case surely somebody or some entity would find that very potential too hard to resist. So, what is it??  Why is RVX being passed over if favor of even some smaller biotech startups with arguably less potential??  In light of ABL’s track record to date, why is even government funding so hard to obtain??

Why is this stock trading at 0.08 cents?  It has reputable people on research boards.  It has Eversana doing something with it, presumably.  Otherwise, why would they still even be in the picture?  It’s a mystery.  The whole thing is a mystery, and in the meantime things just keep getting kicked down the road a couple of years.

I don't get it.